Mulitple System Atrophy Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's "Multiple System Atrophy Pipeline Insight 2026" report provides comprehensive insights about 22+ companies and 24+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Multiple System Atrophy Pipeline? @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Multiple System Atrophy Pipeline Report
• On July 20, 2026- Teva Branded Pharmaceutical Products R&D LLC initiated a phase 2 study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286.
• On July 14, 2026- H. Lundbeck A/S highlighted a study will consist of a screening period of 10 days up to 6 weeks, a 72-week placebo-controlled period (PCP), and will include a 72-week optional open-label treatment extension (OLE) period. Participants in the PCP will be randomized to amlenetug or placebo. All participants entering the OLE will receive amlenetug during the OLE. Participants will receive intravenous infusions approximately every 4 weeks during both the PCP and OLE.
• On July 06, 2026- Biogen conducted a study is to see if starting salanersen before signs or symptoms appear can prevent signs or symptoms of SMA or make them less severe. Researchers will use different tests to learn if motor symptoms are changing, including the World Health Organization (WHO) motor milestones.
• DelveInsight's Multiple System Atrophy Pipeline report depicts a robust space with 22+ active players working to develop 24+ pipeline therapies for Multiple System Atrophy treatment.
• The leading Multiple System Atrophy Companies such as H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Alterity Therapeutics, Dasher Neuroscience Inc., Ionis Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Biocells Medical, Brain Neurotherapy Bio, Inc., Synusight Biotech (Shanghai) Co., Ltd., CytoraStem and others.
• Promising Multiple System Atrophy Therapies such as TEV-56286, YA-101, Foralumab Nasal, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate, ONO-2808, AZD3241, and others.

Want to know which companies are leading innovation in Multiple System Atrophy? @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Multiple System Atrophy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Multiple System Atrophy Pipeline Report also highlights the unmet needs with respect to the Multiple System Atrophy.

Multiple System Atrophy Overview
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects both the autonomic nervous system (which controls involuntary functions such as blood pressure, bladder function, and digestion) and the central nervous system responsible for movement and balance. MSA is classified as an atypical parkinsonian disorder and typically begins in adults aged 50-60 years. Two major subtypes are recognized: MSA-P (parkinsonian type) and MSA-C (cerebellar type). Symptoms usually worsen progressively over time.

Multiple System Atrophy Emerging Drugs Profile
• Amlenetug: H. Lundbeck A/S
Amlenetug is an investigational human monoclonal antibody being developed for the treatment of Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative synucleinopathy. Amlenetug is designed to recognize and bind to all major forms of extracellular alpha-synuclein (α-synuclein), the pathogenic protein believed to drive disease progression in MSA. By binding extracellular α-synuclein, amlenetug is intended to prevent cellular uptake and inhibit the seeding and spread of α-synuclein aggregates between cells. The antibody also possesses an active Fc region that may enhance microglia-mediated immune clearance of α-synuclein/antibody complexes, thereby reducing pathological protein accumulation. For MSA, amlenetug has received several important regulatory designations, including Orphan Drug Designation (EMA), SAKIGAKE Designation (Japan MHLW), Orphan Drug Designation (US FDA), Orphan Drug Designation (Japan MHLW), and Fast Track Designation (US FDA). Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Multiple System Atrophy.

• YA-101: Dasher Neuroscience Inc
YA-101 is an investigational New Chemical Entity (NCE) being developed for the treatment of Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disorder. YA-101 was specifically designed for neurodegenerative diseases and has a dual mechanism of action centered on inhibiting neuroinflammation and enhancing neuroplasticity, with the goal of slowing disease progression and improving neurological function. Preclinical studies reportedly demonstrated improvements in motor-related behavioral impairments in animal models of MSA and ataxia, while a Phase I study in healthy volunteers in Australia established safety and tolerability. YA-101 has received multiple orphan-drug incentives, including U.S. FDA Orphan Drug Designation, Japan MHLW Orphan Drug Designation, and European Medicines Agency (EMA) Orphan Drug Designation for MSA. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Multiple System Atrophy.

• hOMSC300: CytoraStem
hOMSC300 is an investigational allogeneic stem cell therapy for the treatment of Multiple System Atrophy (MSA). The product is based on human Oral Mucosa Stem Cells (hOMSCs), a proprietary stem-cell population derived from oral mucosal tissue. hOMSC300 is administered intrathecally and is intended to act as a disease-modifying therapy by providing neuroprotection, reducing neuroinflammation, and supporting neuronal survival and regeneration. Preclinical MSA models demonstrated that hOMSC300 exerted neuroprotective effects on dopaminergic neurons and dampened neuroinflammatory processes, which are believed to contribute to disease progression in MSA. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Multiple System Atrophy.

If you're tracking ongoing Multiple System Atrophy Clinical trials, this press release is a must-read @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Multiple System Atrophy Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
• Multiple System Atrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.

Multiple System Atrophy Companies
H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Alterity Therapeutics, Dasher Neuroscience Inc., Ionis Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Biocells Medical, Brain Neurotherapy Bio, Inc., Synusight Biotech (Shanghai) Co., Ltd., CytoraStem and others.

Multiple System Atrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as,
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Multiple System Atrophy Products have been categorized under various Molecule types such as,
• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the Multiple System Atrophy Pipeline Report @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Multiple System Atrophy Pipeline Report
• Coverage- Global
• Multiple System Atrophy Companies- H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Alterity Therapeutics, Dasher Neuroscience Inc., Ionis Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Biocells Medical, Brain Neurotherapy Bio, Inc., Synusight Biotech (Shanghai) Co., Ltd., CytoraStem and others.
• Multiple System Atrophy Therapies- TEV-56286, YA-101, Foralumab Nasal, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate, ONO-2808, AZD3241, and others.
• Multiple System Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple System Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Multiple System Atrophy Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Multiple System Atrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple System Atrophy- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. NASP: Swedish Orphan Biovitrum A
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II/III)
11. ABP-671: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. PRX-115: Protalix Biotherapeutics Inc.
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Multiple System Atrophy Key Companies
21. Multiple System Atrophy Key Products
22. Multiple System Atrophy- Unmet Needs
23. Multiple System Atrophy- Market Drivers and Barriers
24. Multiple System Atrophy- Future Perspectives and Conclusion
25. Multiple System Atrophy Analyst Views
26. Multiple System Atrophy Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.